Risikofaktormanagement bei KHK

详细信息    查看全文

• 作者：Ephraim B. Winzer ; Gerhard C. Schuler
• 关键词：Koronare Herzerkrankung ; Risikofaktoren ; Sekund盲rpr盲vention ; Lebensstilver盲nderung
• 刊名：CardioVasc
• 出版年：2013
• 出版时间：September 2013
• 年：2013
• 卷：13
• 期：4
• 页码：34-42
• 全文大小：
• 参考文献：1.Beck EB, Walther C., K枚rner A., Erbs S. Cardiovascular Risk Reduction in Childhood - Evidence and Strategies. European Cardiology 2010;5(2):34鈥?9.
  2.Yusuf S, Hawken S, Ounpuu S et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004 September 11;364(9438):937鈥?52.PubMed CrossRef
  3.(World Health Organization (WHO). The global burden of disease: 2004 update. 2008.
  4.Perk J, de BG, Gohlke H et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012 July;33(13):1635鈥?701.PubMed CrossRef
  5.Gohlke H, Albus C, B枚nner G et al. Leitlinie Risikoadjustierte Pr盲vention von Herz- und Kreislauferkrankungen. http://鈥媗eitlinien dgk org/files/2007_Leitlinie_Risikoadjustierte_Praevention pdf 2007.
  6.Bundes盲rztekammer (B脛K), Kassen盲rztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Chronische KHK - Langfassung. Version 1.X. 2006. 2006.
  7.Bundes盲rztekammer (B脛K), Kassen盲rztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). NationaleVersorgungleitlinie Chronische KHK - Langfassung, Modul Medikament枚se Therapie, 2. Auflage. Version 1.X, 2011. 2011.
  8.Smith SC, Jr., Benjamin EJ, Bonow RO et al. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2011 November 29;124(22):2458鈥?473.PubMed CrossRef
  9.Heitzer T, Meinertz T. [Prevention of coronary heart disease: smoking]. Kardiol 2005;94 Suppl 3:III/30鈥揑II/42.
  10.He J, Vupputuri S, Allen K, Prerost MR, Hughes J, Whelton PK. Passive smoking and the risk of coronary heart disease鈥攁 meta-analysis of epidemiologic studies. N Engl J Med 1999 March 25;340(12):920鈥?26.PubMed CrossRef
  11.Hasdai D, Garratt KN, Grill DE, Lerman A, Holmes DR, Jr. Effect of smoking status on the long-term outcome after successful percutaneous coronary revascularization. N Engl J Med 1997 March 13;336(11):755鈥?61.PubMed CrossRef
  12.Gellert C, Schottker B, Muller H, Holleczek B, Brenner H. Impact of smoking and quitting on cardiovascular outcomes and risk advancement periods among older adults. Eur J Epidemiol 2013 February 9.
  13.Stead LF, Bergson G, Lancaster T. Physician advice for smoking cessation. Cochrane Database Syst Rev 2008;(2):CD000165.PubMed
  14.Ludvig J, Miner B, Eisenberg MJ. Smoking cessation in patients with coronary artery disease. Am Heart J 2005 April;149(4):565鈥?72.PubMed CrossRef
  15.Rigotti NA, Pipe AL, Benowitz NL, Arteaga C, Garza D, Tonstad S. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation 2010 January 19;121(2):221鈥?29.PubMed CrossRef
  16.Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005 October 8;366(9493):1267鈥?278.PubMed CrossRef
  17.Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 2006 August 1;48(3):438鈥?45.PubMed CrossRef
  18.Preiss D, Sattar N. Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence. Clin Endocrinol (Oxf) 2009 June;70(6):815鈥?28.CrossRef
  19.HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013 February 26.
  20.Schwartz GG, Olsson AG, Abt M et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012 November 29;367(22):2089鈥?099.PubMed CrossRef
  21.Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002 December 14;360(9349):1903鈥?913.PubMed CrossRef
  22.Bangalore S, Steg G, Deedwania P et al. beta-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA 2012 October 3;308(13):1340鈥?349.PubMed CrossRef
  23.Bao B, Ozasa N, Morimoto T et al. beta-Blocker therapy and cardiovascular outcomes in patients who have undergone percutaneous coronary intervention after ST-elevation myocardial infarction. Cardiovasc Interv Ther 2013 April;28(2):139鈥?47.PubMed CrossRef
  24.Ozasa N, Morimoto T, Bao B et al. beta-blocker use in patients after percutaneous coronary interventions: One size fits all? Worse outcomes in patients without myocardial infarction or heart failure. Int J Cardiol 2012 November 2.
  25.Dickinson HO, Mason JM, Nicolson DJ et al. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials. J Hypertens 2006 February;24(2):215鈥?33.PubMed CrossRef
  26.Messerli FH, Mancia G, Conti CR et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 2006 June 20;144(12):884鈥?93.PubMed CrossRef
  27.DECODE Study Group, the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001 February 12;161(3):397鈥?05.CrossRef
  28.Schondorf T, Lubben G, Karagiannis E, Erdmann E, Forst T, Pfutzner A. Increased prevalence of cardiovascular disease and risk biomarkers in patients with unknown type 2 diabetes visiting cardiology specialists: results from the DIASPORA study. Diab Vasc Dis Res 2010 April;7(2):145鈥?50.PubMed CrossRef
  29.Ryden L, Standl E, Bartnik M et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007 January;28(1):88鈥?36.PubMed
  30.Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002 February 7;346(6):393鈥?03.PubMed CrossRef
  31.Thomas DE, Elliott EJ, Naughton GA. Exercise for type 2 diabetes mellitus. Cochrane Database Syst Rev 2006;(3):CD002968.
  32.Turnbull FM, Abraira C, Anderson RJ et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009 November;52(11):2288鈥?298.PubMed CrossRef
  33.Gerstein HC, Bosch J, Dagenais GR et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012 July 26;367(4):319鈥?28.PubMed CrossRef
  34.Eilat-Adar S, Eldar M, Goldbourt U. Association of intentional changes in body weight with coronary heart disease event rates in overweight subjects who have an additional coronary risk factor. Am J Epidemiol 2005 February 15;161(4):352鈥?58.PubMed CrossRef
  35.Sierra-Johnson J, Romero-Corral A, Somers VK et al. Prognostic importance of weight loss in patients with coronary heart disease regardless of initial body mass index. Eur J Cardiovasc Prev Rehabil 2008 June;15(3):336鈥?40.PubMed CrossRef
  36.Lavie CJ, De SA, Milani RV. Is there an obesity, overweight, or lean paradox in coronary heart disease? Getting to the 'fat' of the matter. Heart 2013 May;99(9):596鈥?98.PubMed CrossRef
  37.Sattelmair J, Pertman J, Ding EL, Kohl HW, III, Haskell W, Lee IM. Dose response between physical activity and risk of coronary heart disease: a meta-analysis. Circulation 2011 August 16;124(7):789鈥?95.PubMed CrossRef
  38.Schuler G. [Physical activity]. Z Kardiol 2005;94 Suppl 3:III/11鈥揑II/14.
  39.Hambrecht R, Walther C, Mobius-Winkler S et al. Percutaneous coronary angioplasty compared with exercise training in patients with stable coronary artery disease: a randomized trial. Circulation 2004 March 23;109(11):1371鈥?378.PubMed CrossRef
  40.Belardinelli R, Paolini I, Cianci G, Piva R, Georgiou D, Purcaro A. Exercise training intervention after coronary angioplasty: the ETICA trial. J Am Coll Cardiol 2001 June 1;37(7):1891鈥?900.PubMed CrossRef
  41.Taylor RS, Brown A, Ebrahim S et al. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. Am J Med 2004 May 15;116(10):682鈥?92.PubMed CrossRef
  42.Heran BS, Chen JM, Ebrahim S et al. Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst Rev 2011;(7):CD001800.
  43.European Heart Network. Diet, Physical Activity and Cardiovascular Disease in Europe. 2011.
  44.Ladwig K-H, Lederbogen F, Albus C et al. Positionspapier zur Bedeutung psychosozialer Faktoren in der Kardiologie - Update 2013. Kardiologe 2013;7:7鈥?7.CrossRef
  45.Muller-Riemenschneider F, Damm K, Meinhard C et al. Evaluation of medical and health economic effectiveness of non-pharmacological secondary prevention of coronary heart disease. GMS Health Technol Assess 2009;5:Doc16.
  46.Kotseva K, Wood D, de BG, de BD, Pyorala K, Keil U. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009 April;16(2):121鈥?37.PubMed CrossRef
  
• 作者单位：Ephraim B. Winzer (1)
  Gerhard C. Schuler (1)
  
  1. Universit盲t Leipzig 鈥?Herzzentrum, Klinik f眉r Innere Medizin / Kardiologie, Leipzig, Deutschland
  
• 刊物类别：Cardiology; Internal Medicine; Angiology; Diabetes; Endocrinology;
• 刊物主题：Cardiology; Internal Medicine; Angiology; Diabetes; Endocrinology;
• 出版者：Urban & Vogel
• ISSN：1618-3851

文摘

Durch eine gezielte Behandlung von Risikofaktoren kann bei Patienten mit KHK der weitere Krankheitsverlauf ma脽geblich beeinflusst werden. Eine Reduktion von Krankenhauseinweisungen, Verbesserung der Lebensqualit盲t und Verl盲ngerung der Lebenserwartung durch sekund盲rprophylaktische Ma脽nahmen ist gut belegt. Neben einer optimalen medikament枚sen Therapie ist hierf眉r eine oft drastische Ver盲nderung des Lebensstils mit den Schwerpunkten einer konsequenten Nikotinabstinenz, einer gesunden Ern盲hrung und regelm盲脽iger k枚rperlicher Aktivit盲t notwendig. Daten aus der Versorgungsforschung zeigen, dass diese Ziele nur unzul盲nglich erreicht werden. Die Umsetzung der bestehenden Behandlungsleitlinien sollte daher mit Nachdruck verfolgt werden. Forschungsbedarf besteht insbesondere hinsichtlich der prognostischen Bedeutung einer Betablockertherapie bei Patienten mit stabiler KHK und erhaltener LV-Funktion, der prognostischen Bedeutung einer gezielten Gewichtsreduktion bei KHK-Patienten mit 脺bergewicht und Adipositas, der Effektivit盲t psychosozialer Interventionen bei unterschiedlichen Patientengruppen und deren Implementierung in die Routineversorgung sowie hinsichtlich der Optimierung von strukturierten Rehabilitationsprogrammen und der Verbesserung der Patientencompliance. Schl眉sselw枚rter Koronare Herzerkrankung Risikofaktoren Sekund盲rpr盲vention Lebensstilver盲nderung